Latest Commercial Operations News

New Talisman Gold Mines boosted revenue by 121% to NZ$53,000 but posted a $2.26 million net loss as it commissioned a processing plant and secured key commercial agreements.

PolyNovo has completed its pivotal US clinical trial report for NovoSorb BTM and adjusted its FDA Premarket Approval submission timeline to late 2026 to incorporate updated regulatory requirements and additional data.

Argosy Minerals has achieved 99% lithium chloride purity and 94.4% lithium recovery in pilot plant test works for its 12,000tpa Rincon Lithium Project, underpinning its move toward industrial-scale production and advancing its Definitive Feasibility Study.

Recce Pharmaceuticals has signed a non-binding term sheet with a major Middle Eastern pharma player for exclusive rights to commercialise its R327 Topical Gel across the MENA region, targeting a high diabetes burden market.

Great Divide Mining has secured a binding 12-month offtake agreement for 100% of its Challenger gold concentrate production, paving the way for steady export operations and revenue linked to benchmark gold prices.

Nex Metals Explorations and the Wangkatja Tjungula Aboriginal Corporation have formalised a joint venture to combine WTAC’s capital and cultural knowledge with Nex Metals’ technical expertise to pursue gold projects in Western Australia.

Mach7 Technologies has secured a five-year, A$1.7 million subscription contract with US teleradiology provider AMRADNET, slashing deployment time from 12 months to just 45 days.

OncoSil Medical has clinched TGA approval for its OncoSil™ device, the first Class III medical device targeting pancreatic tumours in Australia, paving the way for local commercialisation and enhanced patient access.

Nova Minerals CEO Christopher Gerteisen highlighted progress on the Estelle Project at the Alaska Sustainable Energy Conference, emphasizing the company’s role in establishing a US domestic antimony supply chain backed by US$43.4 million in government funding.

Orezone Gold’s acquisition of the Casa Berardi mine propels it into a diversified mid-tier producer, while Q1 2026 results show a 35% jump in gold output and robust financials despite operational challenges at Bomboré.

Algorae Pharmaceuticals has scaled its AI-driven drug synergy platform from one to 18 anchor drugs, generating over 9 million predictions and identifying thousands of promising combinations for cancer and other diseases.

Saluda Medical’s Australian arm has secured ASIC approval to bypass standalone audited financial reports, cutting costs and streamlining compliance.